300 related articles for article (PubMed ID: 17696946)
1. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
2. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
3. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Chandan VS; Faquin WC; Wilbur DC; Khurana KK
Cancer; 2006 Oct; 108(5):331-6. PubMed ID: 16944537
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
5. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
8. Role of nuclear grooves in the diagnosis of papillary thyroid carcinoma. A quantitative assessment on fine needle aspiration smears.
Francis IM; Das DK; Sheikh ZA; Sharma PN; Gupta SK
Acta Cytol; 1995; 39(3):409-15. PubMed ID: 7539202
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
[TBL] [Abstract][Full Text] [Related]
10. [Practical application of proliferation markers' (MIB-1, PCNA, AgNOR) expression analysis for differential diagnostics of nodular thyroid lesions].
Lewy-Trenda I; Janczukowicz J; Wierzchniewska-Lawska A
Wiad Lek; 2006; 59(1-2):32-7. PubMed ID: 16646289
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
13. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
15. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
16. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
17. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
18. [CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma].
Umeki K; Yamamoto I; Maruta J; Aratake Y; Ono I; Uemura Y; Tanaka T; Toyoda K; Kotani T; Noguchi S; Sakamoto F; Konoe K; Ohtaki S
Rinsho Byori; 1996 Jan; 44(1):42-50. PubMed ID: 8691639
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
20. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
Sack MJ; Astengo-Osuna C; Lin BT; Battifora H; LiVolsi VA
Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
